Comparative Pharmacology
Head-to-head clinical analysis: DEFLAZACORT versus KENALOG IN ORABASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFLAZACORT versus KENALOG IN ORABASE.
DEFLAZACORT vs KENALOG IN ORABASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deflazacort is a glucocorticoid prodrug that is metabolized to its active form, 21-desacetyldeflazacort. It binds to glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
6-90 mg orally once daily; initial dose typically 6-30 mg/day, maintenance as lowest effective dose; taper gradually upon discontinuation.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
None Documented
None Documented
Clinical Note
moderateDeflazacort + Gatifloxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Gatifloxacin."
Clinical Note
moderateDeflazacort + Rosoxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Rosoxacin."
Clinical Note
moderateDeflazacort + Levofloxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Levofloxacin."
Clinical Note
moderateDeflazacort + Trovafloxacin
Terminal half-life of the active metabolite Δ6-deflazacort is 1.1–1.9 hours; parent drug half-life is approximately 1–2 hours. Clinical glucocorticoid effect persists for 12–24 hours due to receptor binding.
Terminal half-life approximately 2-5 hours following mucosal application.
Renal (approximately 70% as metabolites, <5% unchanged); biliary/fecal (approximately 30%)
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Category C
Category C
Corticosteroid
Corticosteroid
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Trovafloxacin."